Correction of abnormal B-cell subset distribution by interleukin-6 receptor blockade in polymyalgia rheumatica

Objectives The aim was to study lymphocyte subsets and circulating cytokines at diagnosis of PMR and after tocilizumab monotherapy. Methods Eighteen untreated patients with PMR were included in a prospective study and received 3-monthly tocilizumab infusions without glucocorticoids. Lymphocyte subset distribution was assessed by flow cytometry and serum cytokines were assayed by a 34-cytokine array and ELISA, at baseline and during follow-up. Baseline data were also compared with age- and sex-matched controls. Results At baseline, total lymphocytes, T-cell subsets and NK cell counts were similar in patients and controls, but patients had significantly lower B-cell counts attributable to lower transitional, naïve and post-switch memory B-cell subsets. Circulating B-cell counts were positively correlated with the PMR activity score (PMR-AS) in untreated active patients at baseline, but subsequently increased to normal values while disease activity was controlled after tocilizumab therapy. Among serum cytokines, IL-6 showed the largest concentration difference between patients and controls, and the serum IL-6 concentration was correlated with baseline PMR-AS. The effects of tocilizumab on serum IL-6 concentration were heterogeneous, and the patients whose serum IL-6 decreased after tocilizumab therapy exhibited a significant increase in circulating B-cell counts. Conclusion In patients with PMR, B-cell lymphopenia and abnormal B-cell subset distribution are associated with disease activity and IL-6 concentration, and both are corrected by the IL-6 antagonist tocilizumab.

[1]  V. Devauchelle-Pensec.  Has the time come for biotherapies in giant cell arteritis and polymyalgia rheumatica? , 2016, Joint, bone, spine : revue du rhumatisme.

[2]  D. van Schaardenburg,et al.  Changes in peripheral blood lymphocyte subsets during arthritis development in arthralgia patients , 2016, Arthritis Research & Therapy.

[3]  R. Spiera,et al.  Brief Report: A Prospective Open‐Label Phase IIa Trial of Tocilizumab in the Treatment of Polymyalgia Rheumatica , 2016, Arthritis & rheumatology.

[4]  A. Saraux,et al.  Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study , 2016, Annals of the rheumatic diseases.

[5]  T. Takeuchi,et al.  Tocilizumab is effective against polymyalgia rheumatica: experience in 13 intractable cases , 2015, RMD Open.

[6]  A. Boots,et al.  Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica. , 2015, Rheumatology.

[7]  M. Hahne,et al.  High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis. , 2015, Rheumatology.

[8]  Simon A. Jones,et al.  Regulatory B cells are induced by gut microbiota–driven interleukin-1β and interleukin-6 production , 2014, Nature Medicine.

[9]  P. Kluin,et al.  Disturbed B Cell Homeostasis in Newly Diagnosed Giant Cell Arteritis and Polymyalgia Rheumatica , 2014, Arthritis & rheumatology.

[10]  S. Tangye,et al.  The origins, function, and regulation of T follicular helper cells , 2012, The Journal of experimental medicine.

[11]  H. Einsele,et al.  Impact of IL-6 receptor inhibition on human memory B cells in vivo: impaired somatic hypermutation in preswitch memory B cells and modulation of mutational targeting in memory B cells , 2011, Annals of the rheumatic diseases.

[12]  H. Einsele,et al.  In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment. , 2011, Arthritis and rheumatism.

[13]  H. Langberg,et al.  Increased muscle interstitial levels of inflammatory cytokines in polymyalgia rheumatica. , 2010, Arthritis and rheumatism.

[14]  M. López-Hoyos,et al.  Circulating cytokines in active polymyalgia rheumatica , 2009, Annals of the rheumatic diseases.

[15]  N. Nishimoto,et al.  Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. , 2008, Blood.

[16]  B. Leeb,et al.  A disease activity score for polymyalgia rheumatica , 2004, Annals of the rheumatic diseases.

[17]  W. Thomson,et al.  IL-6 promoter polymorphism at position -174 modulates the phenotypic expression of polymyalgia rheumatica in biopsy-proven giant cell arteritis. , 2002, Clinical and experimental rheumatology.

[18]  H. Shimizu,et al.  Increased RAHA titer and interleukin-6 levels in the synovial fluid in a patient with polymyalgia rheumatica. , 1993, Internal medicine.

[19]  G. Panayi,et al.  Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis. , 1990, British journal of rheumatology.

[20]  A Muraguchi,et al.  The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells , 1988, The Journal of experimental medicine.